• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The patients' and consumers' working party at the European Medicines Agency: a model of interaction between patients, consumers, and medicines regulatory authorities.

作者信息

Moulon Isabelle, Dedes Nikos

机构信息

European Medicines Agency, London, United Kingdom.

出版信息

J Ambul Care Manage. 2010 Jul-Sep;33(3):190-7. doi: 10.1097/JAC.0b013e3181e59322.

DOI:10.1097/JAC.0b013e3181e59322
PMID:20539145
Abstract

Since the European Medicines Agency was created in 1995, it has engaged in dialogue with its various stakeholders, including patients and other representatives of civil society. The establishment of the Patients' and Consumers' Working Party represented a key step forward in the formalization of this interaction. The working party has played a crucial role in facilitating the integration of patients and consumers in various regulatory activities. This article describes how this group operates and gives a detailed overview of the interaction between the agency and the patients' and consumers' organizations focusing on the main achievements to date.

摘要

相似文献

1
The patients' and consumers' working party at the European Medicines Agency: a model of interaction between patients, consumers, and medicines regulatory authorities.
J Ambul Care Manage. 2010 Jul-Sep;33(3):190-7. doi: 10.1097/JAC.0b013e3181e59322.
2
The innovative medicines initiative: a European response to the innovation challenge.创新药物倡议:欧洲对创新挑战的回应。
Clin Pharmacol Ther. 2012 Mar;91(3):418-25. doi: 10.1038/clpt.2011.321. Epub 2012 Feb 8.
3
The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.欧洲药品管理局:使命、职责概述及癌症药物监管方面的最新举措。
Clin Cancer Res. 2011 Aug 15;17(16):5220-5. doi: 10.1158/1078-0432.CCR-11-0623.
4
Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.在东南欧国家授予药品营销许可:主管当局的观点。
Regul Toxicol Pharmacol. 2010 Jul-Aug;57(2-3):325-32. doi: 10.1016/j.yrtph.2010.04.001. Epub 2010 Apr 10.
5
Provision of information on regulatory authorities' websites.在监管机构网站上提供信息。
Intern Med J. 2008 Jul;38(7):559-67. doi: 10.1111/j.1445-5994.2007.01588.x. Epub 2008 Mar 11.
6
Regulatory review: How do agencies ensure the quality of decision making?监管审查:各机构如何确保决策质量?
Clin Pharmacol Ther. 2013 Sep;94(3):305-8. doi: 10.1038/clpt.2013.127.
7
European Medicines Agency tightens rules on conflict of interest.欧洲药品管理局收紧利益冲突规则。
BMJ. 2010 Oct 19;341:c5902. doi: 10.1136/bmj.c5902.
8
Consumers' views on generic medicines: a review of the literature.消费者对仿制药的看法:文献综述
Int J Pharm Pract. 2009 Apr;17(2):79-88.
9
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.欧洲药品评估局批准的儿童用药。
Eur J Clin Pharmacol. 2002 Nov;58(8):495-500. doi: 10.1007/s00228-002-0511-0. Epub 2002 Sep 25.
10
A report by a working party 1975. Council of Europe European Public Health Community. Abuse of Medicines. I. Self medication.欧洲委员会欧洲公共卫生共同体工作组1975年的一份报告。药物滥用。一、自我药疗。
Drug Intell Clin Pharm. 1976 Jan;10(1):16-33.